An Incredible New Treatment for Bad Cholesterol
Cholesterol, in addition to triglycerides, is two of the key indicators for your cardiovascular health. Maintaining them at the right levels can help you avoid many of the problems you already know about. Therefore, it’s important to learn treatment for bad cholesterol.
Most of us are aware of the fact that the word cholesterol is almost always associated with something negative. But don’t forget that this natural fat substance is also essential for your body to function.
The key is keeping it in balance and maintaining the right levels between the so-called good and bad cholesterol so that they don’t build up in the arteries.
Additionally, your genetic background can determine the accumulation of cholesterol. It can also determine your resistance to certain medications that attempt to lower your cholesterol levels.
Consequently, even if you take these medications, your lipoproteins can remain attached to your artery walls at dangerously high levels. However, there’s a new treatment that can eliminate this risk.
It’s a ray of hope and today we want to tell you all about it.
Evolocumab, a new and more effective treatment for high cholesterol
In 2014, a new pharmaceutical treatment for lowering cholesterol in people who don’t show any improvement under traditional medications came on the market under the name “evolocumab.”
From that moment on, detailed studies were carried out to determine if it could achieve the expected objectives. The results show that yes, the drug is effective. Not only does it manage to reduce bad cholesterol levels it also reverses atherosclerosis.
You may also like:
A new and powerful treatment for cholesterol
In November of this year, the American College of Cardiology published their study in which they analyzed the results achieved so far in the treatment of cholesterol with this new medication, evolocumab.
- The goal of the treatment was to provide therapeutic intervention for people who had a high risk of cardiovascular disease who did not respond to traditional medications.
- The results of the study were very positive. Evolocumab safely and effectively reduced the patients’ levels of bad, or LDL, cholesterol.
- After 24 weeks of treatment, the cholesterol stored in patients’ arteries was minimal. And so their risk of cardiovascular problems had reduced significantly.
- This drug is already an essential therapeutic tool for those who have a genetic background associated with high cholesterol. It’s also ideal for those patients who already have had some kind of cardiovascular disease, or cannot reduce their cholesterol levels with traditional medications.
How does this treatment work?
To effectively lower cholesterol in patients who are resistant to regular drugs, it’s necessary to combine both treatments.
- Doctors still prescribe this new drug with statins.
- Evolocumab acts as an inhibitor of the subtilisn/kexin convertasa protein.
- It is available in a number of countries around the world, with excellent results.
We recommend you also read:
Objective: reverse atherosclerosis
Atherosclerosis is a slow but deadly disease that originates in plaque deposits (atheromas) that are within the arteries.
- Atheromas are not just made up of cholesterol – they also contain calcium and other substances from the bloodstream.
- The main problem is that in the beginning, it has no symptoms. This is a silent disease that doctors can only diagnose by testing.
- If it remains undetected, atherosclerosis can cause problems such as heart attacks and strokes.
- However, another problem for health professionals is that there are many people who simply don’t respond to traditional medications for high cholesterol.
Stephen J. Nichols is the director of the study mentioned earlier who showed the clear effectiveness of evolocumab to treat and reverse atherosclerosis in all patients.
- Their coronary artery scans showed a very positive change after a few months of treatment. It’s finally possible to reduce the risk of cardiovascular diseases to a level.
Who should take this medication?
Adult patients should follow this treatment if they have already been taking the maximum amount of statins and have cardiovascular disease.
- Others include adults with genetic high blood pressure and who already take the maximum dose of statins.
- Adolescents who are 12 and older can take this treatment if they have genetic high blood pressure and already take the maximum dose of statins.
- Any of the patients in the three previous groups should take this drug if they also have a particular intolerance to statins.
You should continue traditional treatments if you only pass the minimal limits for high cholesterol and have no genetic background of this problem.
In all cases, don’t forget to seek advice from a medical professional, take care of your diet and get at least a half hour of exercise every day.
High cholesterol is a serious problem that claims too many lives each year. Let’s do our best to avoid it, and be aware that there are excellent treatments and lifestyle options available.
All cited sources were thoroughly reviewed by our team to ensure their quality, reliability, currency, and validity. The bibliography of this article was considered reliable and of academic or scientific accuracy.
- Ficha Técnica Repatha 140 mg solución inyectable en pluma precargada. Agencia española de medicamentos y y productos sanitarios. https://cima.aemps.es/cima/dochtml/ft/1151016002/FT_1151016002.html
- Informe de Posicionamiento Terapéutico de evolocumab (Repatha®) en hipercolesterolemia (2016). Ministerio de Sanidad. https://www.aemps.gob.es/va/medicamentosUsoHumano/informesPublicos/docs/IPT-evolocumab-repatha.pdf
- Steven E. Nissen, MD, MACC ; Erik SG Stroes, MD (2016). Logro de objetivos después de utilizar un anticuerpo anti-PCSK9 en sujetos intolerantes a las estatinas 3 – GAUSS-3. Colegio de Cardiología de Estados Unidos. https://www.acc.org/latest-in-cardiology/clinical-trials/2016/03/29/22/36/gauss-3
- Página web oficial: https://www.repathahcp.com/
- Inyección de evolocumab. MedlinePlus, en línea: https://medlineplus.gov/spanish/druginfo/meds/a615043-es.html
- Cofan Pujol, M. (2014). Mecanismos básicos. Absorción y excreción de colesterol y otros esteroles. Clínica e Investigación en Arteriosclerosis, 26 (1), 41–47. https://doi.org/10.1016/j.arteri.2013.10.008
- López Farré A, Macaya Miguel C. Libro de la salud cardiovascular del Hospital Clínico San Carlos y la Fundación BBVA. Bilbao: Fundación BBVA; 2009.